Navigation Links
Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin and Lilly Set Date and Time for Conference Call
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... ... the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this ... around the globe, requiring fast track capacity to provide patients with urgently needed ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the solution ... history of eSource, the reasons it did not take off as quickly as people ... the industry is moving towards capturing data electronically for clinical trials and then repurposing ...
(Date:7/18/2020)... ... , ... After research model surgery and catheter implantation, the long journey of ... beginning of a successful study, while protecting and accessing the catheter or device post-surgery ... Surgery from Envigo in a live webinar on Wednesday, August ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
Breaking Biology Technology:
(Date:7/22/2020)... (PRWEB) , ... July 21, 2020 , ... ... digital transformation and innovation in technology and compliance, announces a new solution to ... companies must ensure every layer of their technology stack complies with FDA and ...
(Date:7/10/2020)... FALLS CHURCH, Va. (PRWEB) , ... July 08, ... ... , The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, ... product may need a comparability study, but what is the most effective way ...
(Date:7/2/2020)... , ... July 01, 2020 , ... ... its phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory ... 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer ...
Breaking Biology News(10 mins):